AGN 193109 NEW
| Price | $62 | $92 | $155 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-13 |
Product Details
| Product Name: AGN 193109 | CAS No.: 171746-21-7 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/13 |
Product Introduction
Bioactivity
| 名稱 | AGN 193109 |
| 描述 | AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ). |
| 細(xì)胞實(shí)驗(yàn) | Cells (10,000/cm2) are seeded in complete medium and allowed to attach overnight. The cells are then shifted to defined medium (DM), allowed to equilibrate for 24 h, and treatment is initiated by the addition of fresh DM or DM containing epidermal growth factor (EGF) or retinoid. After 3 days of daily treatment with retinoid, the cells are harvested with 0.025% trypsin, 1 mM EDTA, fixed in isotonic buffer containing 4% formaldehyde, and counted using a counter [2]. |
| 動(dòng)物實(shí)驗(yàn) | Mice (n=6) are treated topically on the dorsal skin with vehicle (92.5% acetone/7.5% DMSO), 0.072 μmol/kg of TTNPB, 1.15 μmol/kg of AGN 193109, or 0.072 μmol/kg of TTNPB plus 0.072, 0.288, or 1.15 μmol/kg of AGN 193109 for 5 days. Mice are euthanized on Day 8 [3]. |
| 體外活性 | AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs [1]. AGN 193109 (100 nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10 nM, and completely shows this effect at 100 nM in ECE16-1 cells. AGN193109 (100 nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increases in levels of K7, K8, and K19 [2]. |
| 體內(nèi)活性 | Topical administration of AGN 193109 at doses of 0.30 or 1.20 μmol/kg significantly mitigates weight loss and cutaneous toxicity associated with concurrent oral TTNPB treatment. A dose of 1.15 μmol/kg AGN 193109 exhibits no apparent toxicity and does not influence spleen weight in mice, yet effectively inhibits the TTNPB-induced spleen weight increase. Furthermore, AGN 193109 notably attenuates ATRA-induced cutaneous toxicity. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 3.92 mg/mL (10 mM) |
| 關(guān)鍵字 | Autophagy | Inhibitor | Retinoic acid receptors | Retinoid X receptors | RAR/RXR | AGN193109 | inhibit | AGN-193109 | AGN 193109 |
| 相關(guān)產(chǎn)品 | Stavudine | Xylitol | Myricetin | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| 相關(guān)庫 | 核受體化合物庫 | 經(jīng)典已知活性庫 | 自噬庫 | 抑制劑庫 | NO PAINS 化合物庫 | 代謝化合物庫 | 脂代謝化合物庫 | 已知活性化合物庫 | 共價(jià)抑制劑庫 | 神經(jīng)元分化化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $160.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $9.80/1KG |
VIP5Y
|
Career Henan Chemical Co
|
2020-02-10 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY